CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker pat...
Phase 2
Dallas, Texas, United States and 18 other locations
and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropy...
Phase 1, Phase 2
Dallas, Texas, United States and 19 other locations
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...
Phase 3
Dallas, Texas, United States and 164 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Dallas, Texas, United States and 66 other locations
and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma...
Phase 2
Dallas, Texas, United States and 10 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Dallas, Texas, United States and 203 other locations
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at wa...
Phase 1
Dallas, Texas, United States and 37 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Dallas, Texas, United States and 195 other locations
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study...
Phase 3
Dallas, Texas, United States and 5 other locations
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), tar...
Phase 1
Dallas, Texas, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal